BMO’s Evan Seigerman: More clarity out of the FDA could drive smaller biotech names in 2026

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

 

BMO’s Evan Seigerman joins ‘Closing Bell’ to talk biopharma stocks heading into the new year.